Financial Incentives for Smoking Cessation

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00128375
First received: August 8, 2005
Last updated: December 12, 2007
Last verified: December 2007

August 8, 2005
December 12, 2007
March 2005
Not Provided
Biochemically verified smoking cessation rates at 6 months post-quit date
Biochemically verified smoking cessation rates at 6 months post-quit date.
Complete list of historical versions of study NCT00128375 on ClinicalTrials.gov Archive Site
  • Enrollment in and completion of community-based smoking cessation programs within the first 6 months after randomization
  • Short-term quit rates at 3 months or 6 months post-quit date
  • Quit rates at 12 months post-quit date
  • Enrollment in and completion of community-based smoking cessation programs within the first 6 months after randomization.
  • Short-term quit rates at 3 months or 6 months post-quit date.
  • Quit rates at 12 months post-quit date.
Not Provided
Not Provided
 
Financial Incentives for Smoking Cessation
Financial Incentives for Smoking Cessation

The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.

Smoking is the leading cause of preventable mortality in United States, accounting for approximately 435,000 of the 2.4 million deaths each year in the United States. Most smokers make multiple attempts to quit smoking, but only 2-3% succeed each year. Smoking cessation programs have proven effective in helping smokers quit, but only about 5% of smokers enroll in smoking cessation programs each year.

Financial incentives have been shown to increase enrollment in smoking cessation programs and short-term quit rates, but have not been well tested as a mechanism for increasing long-term quit rates. The existing evidence suggests that they could be highly effective, particularly among heavy smokers and low income smokers. In addition, financial incentives for smoking cessation will likely be more cost effective than most covered health services and at least as cost effective as other recommended smoking cessation treatments.

This study is a two-arm randomized clinical trial of financial incentives for smoking cessation among a sample of 850 male and female smokers from GE Energy worksites throughout the U.S. Smokers will be randomized to receive either usual care (information about local community-based smoking cessation resources, coverage of prescription drugs and physician visits) or usual care plus a package of financial incentives that includes $100 for completion of a community-based tobacco cessation program, $250 for short-term smoking cessation at either 3 months or 6 months after randomization, and $400 for smoking cessation 6 months post-quit date (biochemically confirmed).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Tobacco Use Disorder
Behavioral: Financial incentives
Not Provided
Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009 Feb 12;360(7):699-709.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
878
April 2008
Not Provided

Inclusion Criteria:

  • Employees of General Electric at work sites in the United States
  • Current smokers who report having smoked at least 5 cigarettes per day for the prior 12 months
  • Age 18 or older

Exclusion Criteria:

  • Current use of other tobacco products, such as chewing tobacco, pipes, or cigars
  • Planning to leave General Electric within the next 18 months
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00128375
802295, 1-R01-DP-000100-03
Not Provided
Not Provided
University of Pennsylvania
Centers for Disease Control and Prevention
Principal Investigator: Kevin G Volpp, MD, PhD University of Pennsylvania
University of Pennsylvania
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP